NIR-II Engineered Exosome Nanotheranostic Probes for "Oriented Blasting" in Orthotopic Glioblastoma
Quick Facts
- Publication title: NIR-II Engineered Exosome Nanotheranostic Probes for "Oriented Blasting" in Orthotopic Glioblastoma
- Journal: ACS Nano
- Year: 2025
- DOI: 10.1021/acsnano.5c01541
- PMID/PMCID: 40539986
Research overview
This study offers an effective approach to glioblastoma therapy by integrating precision-targeted delivery, multimodal imaging, and synergistic therapeutic effects. The findings provide a theranostics platform aimed at overcoming current treatment limitations and improving clinical outcomes for cancer.
Key findings
Glioblastoma (GBM), a highly aggressive and lethal brain tumor, presents a formidable clinical challenge due to its poor prognosis and lack of effective treatment options, underscoring the urgent need for innovative therapeutic strategies.
Here, we report a promising phototheranostic platform based on a near-infrared II (NIR-II) organic molecule, MYM, which combines robust fluorescence with potent photothermal and photodynamic therapeutic capabilities.
To maximize efficacy, MYM was encapsulated in exosomes derived from 293F cells and further functionalized with the iRGD peptide, enhancing both tumor targeting and penetration of the blood-brain barrier (MYM@iRGD-Exo).
In vivo, studies demonstrate that MYM@iRGD-Exo can effectively penetrate the blood-brain barrier and selectively target GBM cells.
Echo Biotech Role
Echo Biotech contributed targeting-peptide/surface modification, EV material/reference-material supply; the study also used or cited ExoBrooch™, ContrExo®.
Related platforms: Echosome®, EV Materials / Reference Materials, Research Reagents & Tools
Related services and capabilities: Targeting Peptide / Surface Modification, EV Material / Reference Material Supply
Related products or reagents: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit, ContrExo® EV Reference Material
References
Original publication: NIR-II Engineered Exosome Nanotheranostic Probes for "Oriented Blasting" in Orthotopic Glioblastoma ACS Nano. 2025. DOI: 10.1021/acsnano.5c01541. PMID/PMCID: 40539986.